Bayer Logo


Volume and Concentration

Gadovist®: double the concentration, half the volume and superior relaxivity*

Gadovist®: double the concentration, half the volume and superior relaxivity*

2x greater volume is required by other macrocyclic agents compared to Gadovist®1–3


1.0 mmol/mL Gadovist®


0.5 mmol/mL GBCA

Competing macrocyclic agents offer 21–31% lower relaxivity at 1.5T compared to Gadovist®4*

Benefits shown with Gadovist®

Higher concentration results in:

  • Lower volume of administration
  • More compact bolus


Higher relaxivity could result in:

  • Enhanced image quality6
  • Improved diagnostic confidence7,8
Adapted from Anzalone N, et al. and Kanal E, et al.6,9 



Gadovist® demonstrated significantly higher sensitivity and accuracy for detection of malignancy compared to ProHance® without a change in specificity7

Follow-up evaluation for a glioma diagnosis using contrast-enhanced T1-weighted images

Gadovist ScanEnhancement with sharp delineation of the anatomic involvement, which was diagnosed as residual/recurrent high-grade glial tumour.


Prohance ScanLess sharp rings of enhancement that were characterized as infection rather than tumour.


 GadovistProHance®Nominal p-value
Sensitivity (n=93)66.7%60.2%p=0.014
Specificity (n=199)97.5%97.5%p=1.000
Accuracy (n=292)87.7%85.6%p=0.034

Sensitivity, specificity and accuracy in determination of malignancy for combined Gadovist® contrast-enhanced vs. combined ProHance®contrast-enhanced imaging (majority reader diagnosis). Full analysis set (n=336).

Lower quality imaging with other macrocyclic agents can lead to less differentiation of malignant vs. benign lesions, which can have an impact on diagnosis and patient care

Gadovist® showed better visualization of enhancing brain lesion vs. Dotarem ®10


A 69-year-old male patient with butterfly glioma (glioblastoma WHO grade IV). Three consecutive T1-weighted images after a single dose (0.1 mmol/kg body weight) of Gadovist® (1) and DOTAREM® (2).

In 66% of assessments (131/199), Gadovist® was better than DOTAREM® in terms of overall preference§¶

Gadovist® provided:

  • Better contrast enhancement of lesions than DOTAREM®
  • Higher lesion-to-brain signal (p<0.001)
  • 9% difference in relative enhancement (p<0.001)



Gadovist® provides superior results compared to other GBCAs


Benefits for you and your patients

  • Less contrast agent used1–3
  • Increased signal and contrast on images6,9
  • Enhanced image quality6
  • Higher sensitivity and accuracy for detection of malignancy7
  • Improved diagnostic confidence7,8


Gd=gadolinium; GBCA=gadolinium-based contrast agent.

* Relaxivity is a marker for the ability of a GBCA to enhance signal intensity on the magnetic resonance image and a prerequisite of technical efficacy of GBCAs.5

† Other GBCAs include DOTAREM® and ProHance®.

‡ At equal contrast dose.

§ Three independent blinded readers assessed off-site their overall diagnostic preference (primary efficacy parameter) based on a matched pairs approach.

¶ Assessments in which a preference for either agent was expressed (p<0.001). No preference recorded in a further 175.


1. GADOVIST® 1.0 Product Monograph, Bayer Inc., March 5, 2018. 2. ProHance® Product Monograph, Bracco Imaging Canada, March 9, 2018. 3. DOTAREM® Product Monograph, Guerbet, imported by Methapharm Inc., April 23, 2018. 4. Szomolanyi P, et al. Comparison of the relaxivities of macrocyclic gadolinium-based contrast agents in human plasma at 1.5, 3 and 7 T, and blood at 3 T. Invest Radiol 2019 [Epub ahead of print]. 5. Tóth É, Helm L and Merbach A. Relaxivity of gadolinium(III) complexes: Theory and mechanism. In: Merbach A, Helm L, Tóth É, eds. The chemistry of contrast agents in medical magnetic resonance imaging. Second Edition ed: John Wiley & Sons, Ltd; 2013:25–81. 6. Anzalone N, et al. Optimizing contrast-enhanced magnetic resonance imaging characterization of brain metastases: relevance to stereotactic radiosurgery. Neurosurgery 2013;72(5):691–701. 7. Gutierrez JE, et al. Safety and Efficacy of Gadobutrol for Contrast-enhanced Magnetic Resonance Imaging of the Central Nervous System: Results from a Multicenter, Double-blind, Randomized, Comparator Study. Magn Reson Insights 2015;8:1–10. 8. Katakami N, et al. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases. Invest Radiol 2011;46(7):411–18. 9. Kanal E, Maravilla K and Rowley HA. Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. AJNR Am J Neuroradiol 2014;35(12):2215–26. 10. Anzalone N, et al. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting. Eur J Radiol 2013;82(1):139–45.